SF
MRNA icon

Synovus Financial’s Moderna MRNA Stock Holding History

Synovus Financial’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,068
Closed -$246K – 925
2024
Q2 		$246K Sell
2,068
-371
-15% -$46.9K ﹤0.01% 776
2024
Q1 		$260K Sell
2,439
-455
-16% -$45.9K ﹤0.01% 767
2023
Q4 		$288K Buy
+2,894
New +$243K ﹤0.01% 726
2023
Q1 		– Sell
-1,235
Closed -$222K – 862
2022
Q4 		$222K Sell
1,235
-2,805
-69% -$459K ﹤0.01% 791
2022
Q3 		$476K Sell
4,040
-230
-5% -$34.9K 0.01% 591
2022
Q2 		$612K Buy
4,270
+221
+5% +$31.6K 0.01% 536
2022
Q1 		$704K Buy
4,049
+300
+8% +$50.5K 0.01% 512
2021
Q4 		$959K Sell
3,749
-86
-2% -$25.1K 0.01% 467
2021
Q3 		$1.48M Sell
3,835
-235
-6% -$86.7K 0.02% 359
2021
Q2 		$950K Sell
4,070
-994
-20% -$178K 0.01% 444
2021
Q1 		$664K Buy
5,064
+786
+18% +$114K 0.01% 489
2020
Q4 		$444K Buy
4,278
+819
+24% +$82.9K 0.01% 570
2020
Q3 		$244K Buy
3,459
+177
+5% +$12.3K ﹤0.01% 644
2020
Q2 		$210K Buy
3,282
+3,082
+1,541% +$169K ﹤0.01% 638
2020
Q1 		$6K Buy
+200
New +$4.6K ﹤0.01% 1722

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Synovus Financial's MRNA Position: Q3 2024 in Review

Synovus Financial sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,068 shares — an estimated $246K sold.

Synovus Financial first reported a position in MRNA in Q1 2020 and held it in 15 quarters. The position peaked at $1.48M in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Synovus Financial reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Synovus Financial sold 2,068 Moderna shares in Q3 2024, an estimated $246K.
  • Synovus Financial first reported a position in Moderna in Q1 2020 and held it in 15 quarters.
  • Synovus Financial's Moderna position peaked at $1.48M in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Synovus Financial's 13F filing for Q3 2024, filed 14 Nov 2024.